spinocerebellar ataxia type 7
ORPHA: 941471 Treatment Available
Overview
Human disease
Available Treatments (1)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| Vigabatrin Orphan | Oral tablet 500mg; Oral powder for solution 500mg sachets | FDA Approved, EMA Approved | 6 | 14d |
Clinical Presentation
Signs and symptoms associated with spinocerebellar ataxia type 7, sourced from HPO and Orphanet clinical annotations.
AtaxiaDysarthriaDysmetriaHyperreflexiaCone/cone-rod dystrophyDysphagiaVisual lossOphthalmoparesisOphthalmoplegiaNystagmusAbnormal fundus morphologyGlobal developmental delayMental deteriorationMotor delayCerebellar atrophyNeonatal hypotoniaMuscle weaknessFailure to thriveCongestive heart failureCerebral atrophyDysdiadochokinesisOrofacial dyskinesiaSomatic sensory dysfunctionBabinski signReduced visual acuityFeeding difficultiesRestless legsMacular degenerationPhotophobiaBlindnessPsychosisHemeralopia
Classification & Codes
Orphanet Code
ORPHA:94147spinocerebellar ataxia type 7
| Orphanet | ORPHA:94147 |
| Treatments | 1 drug(s) |
| Symptoms on record | 32 signs |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO